Expression and prognostic value of estrogen and progesterone receptors status in borderline ovarian tumors and ovarian carcinomas

Orientadores: Sophie Françoise Mauricette Derchain, Liliana Aparecida Lucci de Ângelo AndradeDissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: Introdução: Evidências recentes sugerem que a estimulação hormonal dos esteróides pode estar envolvida no desenvolvimento e prognóstico das neoplasias de ovário. O estrogênio é um importante regulador do crescimento e diferenciação das células ovarianas, enquanto a progesterona pode oferecer proteção contra os efeitos mutagênicos do estrógeno, bloqueando o crescimento e induzindo a diferenciação e apoptose. No entanto, os dados atuais são limitados e os resultados conflitantes. Objetivo: Avaliar os padrões da expressão dos receptores de estrógeno (RE) e de progesterona (RP) em tumores borderline (TBO) e carcinomas de ovário. Foram avaliadas o tempo livre de doença (TLD) e a sobrevida total (ST) das mulheres com carcinoma em relação às expressões destes receptores esteróides. Métodos: Foi avaliada a expressão dos RE/RP em 172 carcinomas de ovário e 38 TBOs, em mulheres operadas de 1993 a 2008 na Universidade Estadual de Campinas - UNICAMP, Brasil, e acompanhadas por até 60 meses. A expressão dos RE/RP foi avaliada por imunoistoquímica (IHQ) em microarranjo de tecidos (TMA). Para as análises estatísticas utilizamos os testes: Qui-quadrados (e exato de Fisher), modelo múltiplo linear generalizado (regressão logística), Cox de risco proporcional, representação de Kaplan Meyer e Mantel-Cox. Não foi possível calcular TLD e ST para os TBOs, pois não ocorreram mortes neste grupo. Resultados: Foram incluídos 28(73.7%) TOBs mucinosos e 10(26.3%) serosos. Os carcinomas de ovário foram compostos por 79(46%) serosos, 44(25.5%) mucinosos, 17(9.8%) endometrióides, 16(9.3%) mistos, 10(5.8%) de células claras, 4(2.4%) adenocarcinoma-SOE e 2(1.2%) de células transicionais. Entre os TBOs, 11(28.9%) foram positivos para a expressão do RE, em comparação com 61(35.5%) carcinomas (p=0.55). Dez (26.3%) dos TBOs e 47(27%) dos carcinomas foram positivos para RP (p=0.90). Nos TBOs, a expressão dos RE e RP foi maior nos serosos ao comparar com a dos mucinosos (p<0.01). Nos carcinomas, a expressão do RE foi maior nos serosos quando comparada com a dos mucinosos (p<0.01) e células claras (p<0.01), e endometrióides quando comparado com os mucinosos (p<0.01). A expressão do RP foi maior nos serosos quando comparada com a dos mucinosos (p<0.01), e endometrióides quando comparado com a dos mucinosos (p<0.01) e serosos (p=0.03). Considerando a expressão combinada dos receptores, a expressão do receptor foi maior nos serosos quando comparads com a dos mucinosos (p<0.01) e células claras (p=0.02), e nos endometrióides quando comparada com a dos mucinosos (p<0.01). Em geral, os tumores serosos e endometrióides foram preponderantementes RE/RP positivos, enquanto os tumores mucinosos e de células claras foram preponderantementes RE/RP negativos. Posteriormente, os tumores com padrões similares na expressão dos RE/RP foram agrupados e analisados: serosos com endometróides e mucinosos com células claras e outros. A expressão dos RE/RP nos carcinomas de ovário não teve nenhuma associação com a idade, estágio do tumor, grau, ascite e doença residual. TLD e ST não foram afetados pela expressão dos RE e RP. TLD não foi afetada por nenhuma das características clínico-epidemiológicas estudadas. ST foi significativamente maior (p<0.01) apenas em mulheres com doenças estádios II-IV e para aqueles com doença residual após a cirurgia (p=0,01). Conclusões: Em geral, os tumores serosos e endometrióides foram preponderantementes RE/RP, enquanto os tumores mucinosos e de células claras foram preponderantementes RE/RP negativos. TLD e ST não foram afetados pela expressão destes receptoresAbstract: Background: Recent lines of evidence suggest that steroid hormonal stimulation may be implicated in the development and prognosis of ovarian malignancies. Estrogen is an important regulator of growth and differentiation of ovarian cells, while progesterone may offer protection against the mutagenic effects of estrogens by blocking cell growth and inducing cell differentiation and apoptosis. However, current data are very limited, and study results are conflicting. Objective: Examine the patterns of estrogen (ER) and progesterone receptors (PR) in borderline tumors (BOTs) and ovarian carcinoma. The disease-free (DFS) and overall survivals (OS) of women with ovarian carcinoma were assessed as related to the expression of these steroid receptors. Methods: The expression of ER/PR was assessed in 172 ovarian carcinomas and 38 BOTs, treated from 1993 to 2008 at the State University of Campinas - UNICAMP, Brazil, and followed up for up to 60 months. ER/PR expression in carcinomas and BOTs was assessed with TMAbased immunohistochemistry. Statistical analysis comprised Chi-squares test (and Fisher's Exact), multivariate generalized linear model using the binomial distribution (logistic regression), Cox Proportional hazards, Kaplan-Meyer method and Mantel-Cox log-rank. We did not calculate DFS or OS for women with BOTS were not calculate because the number of events in that group was null. Results: Twenty-eight(73.7%) mucinous and 10(26.3%) serous BOTs were included. Ovarian carcinomas comprised 79(46%) serous, 44(25.5%) mucinous, 17(9.8%) endometrioid, 16(9.3%) mixed, 10(5.8%) clear-cell, 4(2.4%) adenocarcinoma-NOS and 2(1.2%) transitional cell. Of the BOTs, 11(28.9%) were positive for ER, compared to 61(35.5%) of the carcinomas (p=0.55). Ten cases (26.3%) of the BOTs and 47(27%) of the carcinoma (p=0.90). The expressions of ER and PR were higher in serous BOTs when compared to mucinous tumors (p<0.01). In carcinomas, ER expression was higher in serous compared to mucinous (p<0.01) and clear cell tumors (p<0.01), and in endometrioid compared with mucinous tumors (p<0.01). PR expression was higher in serous compared to mucinous (p<0.01) and in endometroid compared to mucinous (p<0.01) and serous tumors (p=0.03). Considering combined receptor status, receptor expression was higher in serous compared to mucinous (p<0.01) and clear cell tumors (p=0.02), and in endometrioid compared with mucinous tumors (p<0.01). Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. Subsequently, tumors with similar patterns of ER/RP expression were gathered and analyzed: serous with endometrioid and mucinous with clear cell and others. ER/PR status of ovarian carcinomas bore no relation to the age, tumor stage, grade, ascites and residual disease. DSF and OS were not affected by the expression of ER and PR. DFS was not affected by any of the studied epidemiological and clinical features. OS was found to be significantly higher (p<0.01) only for women with disease stages II-IV and for those with residual disease after surgery (p=0.01). Conclusion: Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. The ER/PR status of ovarian carcinomas bore no relation to the age, tumor stage, grade, ascites and residual disease. DSF and OS were not affected by the expression of these receptorsMestradoOncologia Ginecológica e MamáriaMestre em Ciências da Saúd

Immunoexpresion of protein markers of cell differentiation and proliferation in women with low-grade and high-grade serous ovarian carcinoma

Orientador: Sophie Françoise Mauricette DerchainTese (doutorado) - Universidade Estadual de Campinas, Faculdade de Ciências MédicasResumo: Introdução: Apesar da heterogeneidade dos tipos subtipos histológicos entre os carcinomas de ovário (CO), na maioria das vezes são tratados de forma similar. Entre os COs, o tipo seroso é o mais prevalente, corresponde a aproximadamente 80%-85% dos casos. Marcadores proteicos baseados em imuno-histoquímica podem ser utilizados no diagnóstico diferencial entre os COs de baixo e alto grau, e permitindo uma melhor compreensão dos processos associados à quimiorresistência e sobrevida. Objetivo: O objetivo deste estudo foi comparar as expressões imunohistoquímica (IHQ) da WT1, p53, p16, BRCA1, Ki67 e ?-catenina em mulheres com carcinoma seroso de ovário de baixo (CSOBG) e de alto grau (CSOAG), e sua relação com as características clinicopatológicas, resposta à platina e prognóstico. Métodos: Neste estudo retrospectivo, foram incluídas 21 mulheres com CSOBG e 85 com CSOAG. Todos as mulheres foram diagnosticadas e tratadas no Hospital da Mulher Prof. Dr. José Aristodemo Pinotti (CAISM), da Universidade Estadual de Campinas (Unicamp), Brasil, entre janeiro de 1994 a dezembro de 2013, com seguimento avaliado até dezembro de 2016. O projeto foi apro¬vado pelo Comitê de Ética em Pesquisa (CEP). A expressão IHQ da WT1, p53, p16, BRCA1, Ki67 e ?-catenina foram avaliadas em laminas de blocos de TMA (tissue microarray). Resultados: Mulheres com CSOAG estiveram significativamente associadas a estágios avançado (p=0,0003), maiores níveis CA125 (p=0,0002), maior proporção de doença residual pós-cirúrgica (p=0,003), maiores taxas de progressão ou recorrência (p=0,001) quando comparado ao CSOBG. Em relação à idade, menopausa ou resposta à quimioterapia não houve diferenças. A WT1 foi expressa em 71,4% das mulheres com CSOBG e 57,1% das mulheres com CSOAG (p=0,32). As mulheres com CSOAG expressaram a p53 e p16 em 68,3% e 58,5%, respectivamente, em comparação com 9,5% (p<0,001) para ambos os marcadores em mulheres com CSOBG. Na análise univariada, o estadiamento (FIGO), o grau histológico, a expressão da p16 e o algoritmo imuno-histoquímico p53/p16 estiveram relacionados à sobrevida livre de progressão (SLP) e sobrevida global (SG). Na análise multivariada, o estadiamento (FIGO) permaneceu como fator prognóstico independente para SLP e SG, e o grau histológico permaneceu associado a SLP. As mulheres com CSOAG cujos tumores expressaram Ki67 (55,9%) foi significativamente maior em comparação aos CSOGB (9,5%) (p<0,001). A expressão da BRCA1 (38,1% and 21,7%, p=0,12) e ?-catenina não diferiram entre as mulheres com CSOBG e CSOAG (80,9% and 81,9%, respectivamente, p=1,00). As características clínico-patológicas e a resposta à quimioterapia baseada em platina não diferiram de acordo com as imunoexpressões da BRCA1, Ki67 e ?-catenina em nenhum dos grupos. Conclusão: As expressões da p16 e p53 foram significativamente maiores em mulheres com CSOAG, mas não estiveram associadas à resposta à quimioterapia baseada em platina. A expressão da p16 esteve associada com a sobrevida. O algoritmo imuno-histoquímico p53/p16 e a classificação histológica foram concordantes. A expressão da Ki67 foi significativamente maior nas mulheres com CSOAG. A expressão da BRCA1 e ?-catenina não diferiram entre as. A expressão da BRCA1, Ki67 e ?-catenina não estiveram relacionadas às características clínico-patológicas, à resposta à quimioterapia baseada em platina e sobrevidaAbstract: Introduction: Despite the heterogeneity of histological subtypes of ovarian carcinoma they are mostly treated in a similar way. The serous type is the most prevalent and accounts for approximately 80% to 85% of the ovarian carcinomas cases. Protein markers based on immunohistochemistry may be used in differentiation between low and high grade serous ovarian carcinomas allowing a better understanding of processes that may be associated with development of chemoresistance and survival. Objective: The purpose of this study was to compare the immunohistochemical (IHC) expression of WT1, p53, p16, BRCA1, Ki67 and ?-catenin in women with low-grade (LGSOC) and high-grade serous ovarian carcinoma (HGSOC) and its relationship with clinicopathological characteristics, platinum response and prognosis. Methods: For this retrospective cohort study, 21 women with LGSOC and 85 women with HGSOC were included. All patients were diagnosed and treated at the Women¿s Hospital Dr. José Aristodemo Pinotti (CAISM) of Campinas State University (UNICAMP), Brazil, from 1994 to 2013 and followed-up until December 2016. The Research Ethics Committee approved the project. Histological diagnosis was rendered following the World Health Organization (WHO) criteria. IHC expression of WT1, p53, p16, BRCA1, Ki67 and ?-catenin was assessed using tissue microarray slides. Results: Women with HGSOC were significantly more likely to have advanced stage disease (p=0.0003), higher CA125 levels (p=0.0002), post-surgery residual disease (p=0.003) and higher rates of disease progression or recurrence (p=0.001) when compared with women harboring LGSOC. In relation to age, menopause or response to chemotherapy there was no significant difference. WT1 was expressed in 71.4% of LGSOC and 57.1% of HGSOC (p=0.32). HGSOC patients expressed p53 and p16 in 68.3% and 58.5% of the cases, respectively, compared to 9.5% (p <0.001) for both markers in women with LGSOC. In univariate analysis, FIGO staging system, histological grade, p16 and immunohistochemical p53/p16 algorithm were significantly associated with progression free survival (PFS) and overall survival (OS). In multivariate analysis, FIGO remained independent prognostic factor for PFS and OS and histological grade remained associated only with PFS. The percentage of women with HGSOC whose tumours expressed Ki67 (55.9%) was significantly higher compared with women with LGSOC (9.5%) (p<0.001). The expression of BRCA1 (38.1% LGSOC vs 21.7% HGSOC, p=0.12) and ?-catenin did not differ between LGSOC and HGSOC (80.9% and 81.9%, respectively, p=1.00). The clinicopathological features and the response to platinum-based chemotherapy did not differ according to the BRCA1, Ki67 and ?-catenin IHC expression in either group. Conclusion: p53 and p16 expressions were significantly higher in women with HGSOC, but were not associated with response to platinum chemotherapy. The expression of p16 was associated with survival. Immunohistochemical p53/p16 algorithm and histological grade closely match. Ki67 expression was significantly higher in HGSOC. BRCA1 and ?-catenin expression did not differ between LGSOC and HGSOC samples. BRCA1, Ki67 and ?-catenin expression was neither related to clinicopathological features, response to platinum-based chemotherapy nor survivalDoutoradoOncologia Ginecológica e MamáriaDoutor em Ciências da Saúde2012/15059-8306583/2014-3FAPESPCNP

Survival Of Women With Ovarian Carcinomas And Borderline Tumors Is Not Affected By Estrogen And Progesterone Receptor Status.

To examine the patterns of estrogen receptor (ER) and progesterone receptor (PR) expression in borderline ovarian tumors (BOTs) and ovarian carcinomas. We also assessed the disease-free survival (DFS) and overall survival (OS) in women with ovarian carcinoma, in relation to ER and/or PR expression. We examined ER/PR expression in 38 BOTs and 172 ovarian carcinomas removed from patients treated at the State University of Campinas-UNICAMP (Brazil), from 1993 to 2008 and followed for up to 60 months using tissue microarray-based immunohistochemistry. Twenty-eight (73.7%) mucinous and 10 (26.3%) serous BOTs were included. Ovarian carcinomas consisted mainly of 79 (46.0%) serous, 44 (25.5%) mucinous, 17 (9.8%) endometrioid, 10 (5.8%) clear-cell types. There was no significant difference of the ER/PR expression between BOT and ovarian carcinoma (p=0.55 for ER alone, 0.90 for PR alone, and 0.12 for combined expression). The level of ER/PR expression in BOTs was significantly higher in serous than in mucinous tumors (p<0.01). In carcinomas, ER/PR was higher in serous tumors than in mucinous (p<0.01) and clear cell tumors (p=0.02), and higher in endometrioid tumors than in mucinous tumors (p<0.01). DFS was affected neither by the clinical characteristics nor by combined steroid receptor status. OS was found to be significantly worse (p<0.01) only in women with stages II-IV tumors and those with residual disease after surgery (p<0.01). Overall, serous and endometrioid tumors were predominantly ER/PR positive, whereas mucinous and clear-cell tumors were preponderantly ER/PR negative. DFS and OS were not affected by ER/PR expression.24167-7

[laparoscopy For Diagnosis And Treatment Of Adnexal Masses].

To assess clinical factors, histopathologic diagnoses, operative time and differences in complication rates between women undergoing laparoscopy or laparotomy to diagnose and treat an adnexal mass and their association with laparoscopy failure. In this prospective study, 210 women were invited to participate and 133 of them were included. Eighty-eight women underwent laparotomy and 45 underwent laparoscopy. Fourteen of the 45 laparoscopies were converted to laparotomy intraoperatively. We assessed whether age, body mass index (BMI), previous abdominal surgeries, CA-125, Index of Risk of Malignancy (IRM), tumor diameter, histological diagnosis, operative time and surgical complication rates differed between the laparoscopy group and the group converted to laparotomy and whether those factors were associated with conversion of laparoscopy to laparotomy. We also assessed surgical logs to evaluate the reasons, as stated by the surgeons, to convert a laparoscopy to laparotomy. In this research, 30% of the women had malignant tumors. CA-125, IRM, tumor diameter and operative times were higher for the laparotomy group than the laparoscopy group. Complication rates were similar for both groups and also for the successful laparoscopy and unsuccessful laparoscopy groups. The surgical complication rate in women with benign tumors was lower for the laparoscopy group than for the laparotomy group. The factors associated with conversion to laparotomy were tumor diameter and malignancy. During laparoscopy, adhesions a large tumor diameter were the principal causes of conversion. This study suggests that laparoscopy for the diagnosis and treatment of adnexal masses is safe and does not increase complication rates even in patients who need conversion to laparotomy. However, when doubt about the safety of the procedure and about the presence of malignancy persists, consultation with an expert gynecology-oncologist with experience in advanced laparoscopy is recommended. A large tumor diameter was associated with the necessity of conversion to laparotomy.36124-3

Laparoscopy for diagnosis and treatment of adnexal masses

PURPOSE: To assess clinical factors, histopathologic diagnoses, operative time and differences in complication rates between women undergoing laparoscopy or laparotomy to diagnose and treat an adnexal mass and their association with laparoscopy failure.METHODS: In this prospective study, 210 women were invited to participate and 133 of them were included. Eighty-eight women underwent laparotomy and 45 underwent laparoscopy. Fourteen of the 45 laparoscopies were converted to laparotomy intraoperatively. We assessed whether age, body mass index (BMI), previous abdominal surgeries, CA-125, Index of Risk of Malignancy (IRM), tumor diameter, histological diagnosis, operative time and surgical complication rates differed between the laparoscopy group and the group converted to laparotomy and whether those factors were associated with conversion of laparoscopy to laparotomy. We also assessed surgical logs to evaluate the reasons, as stated by the surgeons, to convert a laparoscopy to laparotomy.RESULTS: In this research, 30% of the women had malignant tumors. CA-125, IRM, tumor diameter and operative times were higher for the laparotomy group than the laparoscopy group. Complication rates were similar for both groups and also for the successful laparoscopy and unsuccessful laparoscopy groups. The surgical complication rate in women with benign tumors was lower for the laparoscopy group than for the laparotomy group. The factors associated with conversion to laparotomy were tumor diameter and malignancy. During laparoscopy, adhesions a large tumor diameter were the principal causes of conversion.CONCLUSION: This study suggests that laparoscopy for the diagnosis and treatment of adnexal masses is safe and does not increase complication rates even in patients who need conversion to laparotomy. However, when doubt about the safety of the procedure and about the presence of malignancy persists, consultation with an expert gynecology-oncologist with experience in advanced laparoscopy is recommended. A large tumor diameter was associated with the necessity of conversion to laparotomy.OBJETIVO: Avaliar o uso da laparoscopia como método diagnóstico e terapêutico na abordagem inicial de tumores anexiais em população de risco para malignidade, bem como fatores clínicos associados à falha do método e conversão para laparotomia, e comparar taxas de complicação com pacientes cuja abordagem inicial se deu por laparotomia.MÉTODOS: Estudo prospectivo com 210 mulheres com exames de imagem prévios constando tumor anexial, das quais 133 foram incluídas. Destas, 45 foram submetidas à laparoscopia e 88, à laparotomia. Catorze das 45 cirurgias iniciadas por laparoscopia foram convertidas a laparotomia no intraoperatório. Foi avaliado se idade, índice de massa corporal (IMC), número de cirurgias abdominais prévias, CA-125, índice de risco de malignidade (IRM), diâmetro do tumor, duração da cirurgia e número de complicações cirúrgicas diferiram entre os grupos laparoscopia, laparoscopia com conversão à laparotomia e laparotomia. Foi também avaliado o motivo reportado pelos cirurgiões como falha da laparoscopia e a razão da conversão para laparotomia.RESULTADOS: A taxa de tumores malignos neste estudo foi de 30%. Houve diferença nos valores de CA-125, IRM e diâmetro do tumor entre os grupos laparoscopia e laparotomia. A duração da cirurgia foi maior no grupo de laparoscopias convertidas à laparotomia, porém as taxas de complicação cirúrgica foram semelhantes entre os grupos e, quando isolados os tumores benignos, as taxas de complicação cirúrgica da laparoscopia se mostraram inferiores à laparotomia. Dentre os fatores em estudo, apenas o tamanho do tumor esteve relacionado à conversão para laparotomia.CONCLUSÃO: Este estudo sugere que a abordagem inicial de pacientes com tumores anexiais de risco para malignidade é segura e não aumenta as taxas de complicação, mesmo em pacientes que necessitem de conversão para laparotomia; entretanto, nos casos de dúvida, é preciso avaliar a necessidade de consultar ginecologistas com experiência em laparoscopia avançada e no tratamento de câncer. O tamanho do tumor esteve relacionado à conversão para laparotomia.12413

Serous and non-serous ovarian carcinoma: histological tumor type as related to the grade of differentiation and disease prognosis

PURPOSE: To compare the clinical-pathological features of women with serous and non-serous ovarian tumors and to identify the factors associated with survival. METHODS: In this reconstructed cohort study, 152 women with ovarian carcinoma, who attended medical consultations between 1993 and 2008 and who were followed-up until 2010 were included. The histological type was clearly established for all women: 81 serous carcinomas and 71 non-serous tumors (17 endometrioid, 44 mucinous and 10 clear cell carcinomas). The crude and adjusted odds ratios (OR), with the respective 95% confidence intervals (95%CI), were calculated for the clinical and pathological features, comparing serous and non-serous histological types. The Hazard Ratios (HR) with 95%CI was calculated for overall survival, considering the clinical and pathological features. RESULTS: Comparison of serous to non-serous tumor types by univariate analysis revealed that serous tumors were more frequently found in postmenopausal women, and were predominantly high histological grade (G2 and G3), advanced stage, with CA125&gt;250 U/mL, and with positive peritoneal cytology. After multivariate regression, the only association remaining was that of high histological grade with serous tumors (adjusted OR 15.1; 95%CI 2.9-77.9). We observed 58 deaths from the disease. There was no difference in overall survival between women with serous carcinoma and women with non-serous carcinoma (HR 0.4; 95%CI 0.1 - 1.1). It was observed that women aged 50 years or less (HR 0.4; 95%CI 0.1-0.9) and those who were in menacne (HR 0.3; 95%CI 0.1-0.9) had a longer survival compared respectively to those above 50 years of age and menopaused. High histological grade (G2 and G3) (p<0.01), stages II-IV (p<0.008) and positive cytology (p<0.001) were significantly associated with worse prognosis. CA125 and the presence of ascites did not correlate with survival. Survival was poor when the disease was diagnosed in stages II to IV and compared to stage I (log-rank p<0.01) regardless of histological type (serous and non-serous). CONCLUSIONS: The proportion of high histological grade (G2 and G3) was significantly higher among serous than non-serous carcinomas. Serous and non-serous histological types were not related to overall survival.OBJETIVO: Comparar as características clinicopatológicas de mulheres com carcinoma seroso e não seroso de ovário e identificar os fatores associados à sobrevida. MÉTODOS: Foram incluídas, neste estudo de coorte reconstituída, 152 mulheres com carcinoma de ovário, atendidas entre 1993 e 2008 e seguidas até 2010, nas quais o tipo histológico foi claramente estabelecido: 81 pacientes com carcinoma seroso e 71 pacientes com tumores não serosos (17 com carcinoma endometrioide, 44 com carcinoma mucinoso e 10 com carcinoma de células claras). Foram calculados os odds ratios (OR) brutos e os OR ajustados com os respectivos intervalos de confiança (IC95%) para as características clínicas e patológicas, comparando tumores serosos e não serosos. Foram calculados os Hazard Ratios (HR) com os respectivos IC95% em relação à sobrevida geral, para as variáveis clínicas e patológicas. RESULTADOS: Comparando os tipos seroso e não seroso, na análise univariada, os tumores serosos foram mais frequentes na pós-menopausa e eram preponderantemente carcinomas de alto grau histológico (G2 e G3), em estádios avançados, com CA125&gt;250 U/mL e citologia peritoneal positiva. Após regressão múltipla, apenas o alto grau histológico se manteve associado com tumores serosos (OR ajustado 15,1; IC95% 2,9-77,9). Observamos 58 óbitos pela doença. O tipo histológico (seroso ou não seroso) não esteve associado com a sobrevida (HR 0,4; IC95% 0,1-1,1). Mulheres com idade de 50 anos ou menos (HR 0,4; IC95% 0,1-0,9) e aquelas que estavam em menacme (HR 0,3; IC95% 0,1-0,9) tiveram maior sobrevida quando comparadas, respectivamente, àquelas com idade acima de 50 anos e na menopausa. Carcinomas de alto grau histológico (G2 e G3) (p<0,01), estádio II a IV (p<0,008) e citologia peritoneal positiva (p<0,001) estiveram significativamente relacionados com pior prognóstico. O nível sérico de CA125 e a presença de ascite não se relacionaram com a sobrevida. A sobrevida foi menor quando a doença foi diagnosticada em estágios II a IV em comparação àquela das mulheres diagnosticadas no estádio I (log-rank p<0,01) independentemente do tipo histológico (seroso ou não seroso). CONCLUSÕES: A proporção de carcinomas de alto grau histológico (G2 ou G3) foi significativamente maior entre os carcinomas serosos comparados com não serosos. O tipo histológico seroso ou não seroso não esteve associado à sobrevida total.19620

Strict Criteria For Selection Of Laparoscopy For Women With Adnexal Mass.

We compared the indication of laparoscopy for treatment of adnexal masses based on the risk scores and tumor diameters with the indication based on gynecology-oncologists' experience. This was a prospective study of 174 women who underwent surgery for adnexal tumors (116 laparotomies, 58 laparoscopies). The surgeries begun and completed by laparoscopy, with benign pathologic diagnosis, were considered successful. Laparoscopic surgeries that required conversion to laparotomy, led to a malignant diagnosis, or facilitated cyst rupture were considered failures. Two groups were defined for laparoscopy indication: (1) absence of American College of Obstetrics and Gynecology (ACOG) guideline for referral of high-risk adnexal masses criteria (ACOG negative) associated with 3 different tumor sizes (10, 12, and 14 cm); and (2) Index of Risk of Malignancy (IRM) with cutoffs at 100, 200, and 300, associated with the same 3 tumor sizes. Both groups were compared with the indication based on the surgeon's experience to verify whether the selection based on strict rules would improve the rate of successful laparoscopy. ACOG-negative and tumors ≤10 cm and IRM with a cutoff at 300 points and tumors ≤10cm resulted in the same best performance (78% success = 38/49 laparoscopies). However, compared with the results of the gynecology-oncologists' experience, those were not statistically significant. The selection of patients with adnexal mass to laparoscopy by the use of the ACOG guideline or IRM associated with tumor diameter had similar performance as the experience of gynecology-oncologists. Both methods are reproducible and easy to apply to all women with adnexal masses and could be used by general gynecologists to select women for laparoscopic surgery; however, referral to a gynecology-oncologist is advisable when there is any doubt.1